Post 2016 US Election, we move on and get back to business with an in-depth review of some new science and clinical data.
Yes, it’s time for another Bushidō – “Way of the Warrior” – guide to the key ASH abstracts!
Here we focus on acute myeloid leukemia (AML), a difficult and challenging disease to treat with a high unmet medical need for new effective therapies.
In this Preview we look at key companies in the AML space, as well as a look at what’s happening in classic targets and also some new ones that are receiving notable attention, both preclinically and also in the clinic.
To learn more insights, subscribers can log-in
We have written about small biotechs and big pharma a lot on this blog, particularly when they have exciting new developments in their pipeline to review and consider. Increasingly, we have also begun to look at the early phase companies because often, that is where some fresh ideas and approaches are being developed and tested.
They’re also not beholden to the norm in terms of thinking that’s non-linear and many are academic start-ups that began life as thought leaders doing their own research and eventually VCs get interested, enabling financing to be raised. The downside of this for some of our readers is that they’re usually not investable as a private company (sorry about that), but we have a broad church here on BSB and instead these small companies attract the interest of enlightened pharma companies who want to license early compounds in areas they are interested in or gain knowledge about a new field of research before buying elsewhere. In other cases, the approach pays off in clinical trials and we see the IPOs emerge from companies such as Juno Therapeutics.
One company that neatly fits this bill is Syros Pharmaceuticals, an academic spin-off from the Whitehead Institute of MIT and Dana Farber Cancer Institute in Boston based on the pioneering work of Drs Richard Young, Jay Bradner and Nathanael Gray.
Regular readers will remember our original article their the scientific work on gene transcription factors at AACR last year, which included a fascinating interview with Dr Young. That was probably one of my favourite interviews of 2014 – I was inspired!
It’s now time to look at the company and entertain some strategic thinking about where they’re coming from and where they’re going with clinical development. The CEO, Dr Nancy Simonian, kindly agreed to an interview and be put in the ‘hot seat,’ so to speak.
This screenshot from the Syros website sums up their philosophy: Better medicines through gene control.
To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content.
For the third part of the series on the AACR Previews, I wanted to switch directions and take a broad look at five completely different approaches in cancer research that we haven’t discussed on Biotech Strategy before and look at how they are doing and which ones might be promising going forward. Some of these scientific developments could potentially impact existing compounds in development.
Companies mentioned: Exelixis, Roche/Genentech, GSK, Clovis, AstraZeneca, Oncoethix
Compounds discussed: cobimetinib, DEDN6526A, ipatasertib, dabrafenib, trametinib, OTX015, JQ1, CO–1686, AZD9291
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.